|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 155.38 USD | -1.50% |
|
+0.66% | +7.44% |
| 04-23 | Boston Scientific lifts profit view as robust demand expected to shield tariff impact | RE |
| 04-23 | European pharma companies push for higher drug prices in EU amid U.S. tariff threats | RE |
| Capitalization | 374B 329B 309B 282B 519B 31,962B 587B 3,605B 1,409B 14,332B 1,405B 1,375B 53,276B | P/E ratio 2025 * |
16.3x | P/E ratio 2026 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise value | 375B 330B 309B 282B 520B 32,003B 587B 3,609B 1,410B 14,350B 1,406B 1,377B 53,343B | EV / Sales 2025 * |
4.11x | EV / Sales 2026 * | 3.83x |
| Free-Float |
77.08% | Yield 2025 * |
3.27% | Yield 2026 * | 3.47% |
More valuation ratios
* Estimated data
More news
Last Transcript: Johnson & Johnson
More recommendations
More press releases
More news
| 1 day | +0.14% | ||
| 1 week | +0.66% | ||
| Current month | -6.31% | ||
| 1 month | -5.04% | ||
| 3 months | +4.88% | ||
| 6 months | -4.58% | ||
| Current year | +7.44% |
| 1 week | 152.1 |  | 159.44 |
| 1 month | 141.5 | | 166.63 |
| Current year | 140.68 | | 169.99 |
| 1 year | 140.68 | | 169.99 |
| 3 years | 140.68 | | 186.69 |
| 5 years | 133.65 | | 186.69 |
| 10 years | 81.79 | | 186.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 62 | 02/01/2022 |
Joseph Wolk
DFI | Director of Finance/CFO | 58 | 30/06/2018 |
Penny M. Heaton
CTO | Chief Tech/Sci/R&D Officer | 60 | 31/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Anne Mulcahy
BRD | Director/Board Member | 71 | 22/10/2009 |
Mark McClellan
BRD | Director/Board Member | 61 | 14/10/2013 |
Mary Beckerle
BRD | Director/Board Member | 70 | 08/06/2015 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 14.01% | 378 M€ | +11.47% | - | |
| 12.91% | 21 M€ | -8.43% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.50% | +0.66% | +4.20% | -15.26% | 380B | ||
| +0.23% | +9.95% | +13.41% | +186.39% | 743B | ||
| +1.88% | -1.14% | +5.46% | +11.69% | 307B | ||
| +4.85% | -6.18% | -53.28% | +6.08% | 266B | ||
| +1.30% | +2.54% | +14.30% | -29.54% | 251B | ||
| +0.24% | +2.43% | +4.05% | +5.40% | 212B | ||
| +2.19% | +0.41% | -7.89% | -1.35% | 210B | ||
| -0.29% | -0.54% | -37.97% | -8.69% | 199B | ||
| -0.18% | -5.45% | +2.20% | +8.78% | 150B | ||
| +0.82% | -0.11% | +58.89% | +66.87% | 132B | ||
| Average | +1.16% | +2.15% | +0.34% | +23.04% | 285.02B | |
| Weighted average by Cap. | +1.06% | +4.20% | +0.84% | +49.03% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 91.32B 80.33B 75.37B 68.75B 127B 7,795B 143B 879B 344B 3,495B 343B 335B 12,993B | 94.83B 83.42B 78.27B 71.4B 132B 8,095B 149B 913B 357B 3,630B 356B 348B 13,493B |
| Net income | 21.52B 18.93B 17.76B 16.2B 29.85B 1,837B 33.72B 207B 80.96B 824B 80.74B 79.05B 3,062B | 21.92B 19.28B 18.09B 16.5B 30.41B 1,871B 34.34B 211B 82.46B 839B 82.23B 80.52B 3,119B |
| Net Debt | 473M 416M 390M 356M 656M 40.37B 741M 4.55B 1.78B 18.1B 1.77B 1.74B 67.29B | -11.24B -9.89B -9.28B -8.46B -15.59B -959B -17.61B -108B -42.27B -430B -42.16B -41.28B -1,599B |
More financial data
* Estimated data
Employees
138,100
Sector
Pharmaceuticals
Calendar
03:00pm
- Annual General Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/04/25 | 155.38 $ | -1.50% | 9,099,438 |
| 22/04/25 | 157.75 $ | +0.53% | 7,136,321 |
| 21/04/25 | 156.92 $ | -0.35% | 6,285,438 |
| 17/04/25 | 157.47 $ | +2.31% | 10,981,067 |
| 16/04/25 | 153.91 $ | +0.19% | 7,987,296 |
Delayed Quote Nyse, April 23, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
155.38USD
Average target price
169.84USD
Spread / Average Target
+9.31%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JNJ Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition